Omada Health, Inc. Common Stock

Omada Health's 71.2 RSI signals aggressive overbought conditions despite the stock sitting below its 52-week high, suggesting momentum has detached from valuation reality. The absence of a P/E ratio indicates the company remains unprofitable, yet the $1.1B market cap assigns substantial enterprise value to a pre-earnings business. A 10.43% short float provides moderate skeptical positioning, leaving room for either capitulation or a potential squeeze if positive catalysts emerge. The overbought technical reading without profitable operations creates a precarious setup—enthusiasm appears front-run relative to fundamental proof points.